Other lipid agents × blood pressure

TrialDiabetes care2016

Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.

Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study GroupPubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 1,310 people · 2016

Randomised comparison

Lowered adverse events & safety

−58%−72% to −37%

Bigger than 8 in 10 for adverse events & safety

As reported

OR 0.42, 95% CI 0.28–0.63

Range includes no effect

No clear effect on blood pressure

1.2×0.6× to 2.4×

12 in 100 instead of 10

Bigger than 4 in 10 on the map

As reported

OR 1.21, 95% CI 0.61–2.40

Range includes no effect

No clear effect on blood pressure

+13%−29% to +79%

12 in 100 instead of 10

Bigger than 2 in 10 on the map

As reported

OR 1.13, 95% CI 0.71–1.79

Three numbers in the abstract

the abstract, start to end

with standard (adjusted odds ratio [aOR] 0.42, 95% CI 0.28-0.63, P < 0.0001), 7.5% with intensive blood pressure treatment versus 6.0% for standard (aOR 1.21, 95% CI 0.61-2.40, P = 0.59), and 11.8% with fenofibrate versus 10.2% with placebo (aOR 1.13, 95% CI 0.71-1.79, P = 0.60) in

← favours treatmentfavours comparator →
could be chance
Adverse events & safety
OR 0.420.28–0.63
Blood pressure
OR 1.210.61–2.40
Blood pressure
OR 1.130.71–1.79
Other lipid agentsBlood pressureAdverse events & safety

Other lipid agents × blood pressurehelps?no deciding trial

unlikelylikely
0.25only evidence

Other lipid agents × adverse events & safetyharms?mixed

unlikelylikely
0.000.00 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

75 papers cite itlatest 60 shown

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 27289122